亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Antisense Oligonucleotide Therapy for B Cell Mediated Cancers

技術優勢: Targets leukemia cells Conjugated for antisense oligonucleotide Targets precursor B cells Monoclonal antibody

詳細技術說明: Antisense compounds have been used to modulate protein expression by binding to a target mRNA encoding the protein. Application of oligonucleotide-based technologies in cancer is promising but has had limited success in vivo due to the ineffective cell-targeting. Better targeting is needed to improve therapeutic efficacy of oligonucleotide-based cancer therapies in vivo. Researchers at the University of California, Davis have developed a precursor B cell (pre-B) acute lymphoblastic leukemia (ALL) cell targeting compound by directly conjugating an antisense oligonucleotide with an anti-CD22 antibody. This method specifically targets a transcription factor identified to be involved in pre-B ALL cell survival. In-vivo therapeutic efficacy has been successfully tested in pre-B ALL xenograft mouse models and Reh cell line, as well as patient-derived leukemia cells. Utilizing this method also provides new opportunities to treat and target B cells associated with leukemia, lymphoma and autoimmune disorders.

*Abstract: Researchers at the University of California, Davis have developed a targeted therapy using an antisense oligonucleotide (ASO) to treat precursor B cell (pre-B) acute lymphoblastic leukemia (ALL).

*Principal Investigation: Name: Nitin Nitin
Department:

Name: Noriko Satake
Department:

Name: Joseph Tuscano
Department:

Name: Shuling Guo
Department:

Name: Michael Oestergaard
Department:

Name: Punit Seth
Department:

其他

Additional Technologies by these Inventors

Tech ID/UC Case

29215/2014-686-0

Related Cases

2014-686-0

欲了解更多信息，請點擊這裡